| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members take part in CDA [Canadian Drug Agency] surveys and sessions. | 視覺障礙
> 視覺障礙 | 監管合作夥伴關係
> 與監管機構合作 | Do not know | National | Sometimes | 119063928324 |
| Submissions to the provincial government and advisory briefs to the to INESSS [Institut National d'Excellence en Santé et en Services Sociaux – National Institute of Excellence in Health and Social Services]. | 視覺障礙
> 黃斑部退化 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100,000 | Regional | Regularly | 115043530962 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | 神經系統
> 多發性硬化症 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 10,000 | National | Regularly | 115059223657 |
| Patient Group Evidence submissions to Canada's Drug Agency (CADTH [Canadian Agency for Drugs and Technologies in Health]), INESSS [Institut national d'excellence en santé et en services sociaux - National Institute of Excellence in Health and Social Services] and BC [British Columbia] Pharmacare. | 呼吸系統
> 慢性阻塞性肺病 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100,000 | National | Sometimes | 119013149214 |
| Canadian Drug Agency patient submissions. INESSS [Institut national d'excellence en santé et en services sociaux] (Quebec) patient submissions. | 呼吸系統
> 哮喘及過敏症 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100,000 | National | Regularly | 119021123567 |
| Canadian Drug Agency patient submissions. | 呼吸系統
> 哮喘及過敏症 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100,000 | National | Regularly | 119021123567 |
| HTA [Health Technology Assessment] submissions. | 皮膚
> 皮膚狀況：大多數類型 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100,000 | National | Regularly | 119022981107 |
| We write letters to pCPA [pan-Canadian Pharmaceutical Alliance] when necessary. We write submissions to the HCA [Health Canada Assessment] process (CDA [Canada's Drug Agency] and INESSS [National Institute for Excellence in Health and Social Services]). | 癌症
> 癌症：血液 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 10,000 | National | Regularly | 119031899906 |
| We do regular submissions for HTA [Health Technology Assessment] and have active relationships with government decision-makers at many levels. | 腸胃
> 腸胃：大多數類型 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100,000 | National | Regularly | 119037340441 |
| We do regular submissions for HTA [Health Technology Assessment]. | 腸胃
> 腸胃：大多數類型 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100,000 | National | Regularly | 119037340441 |
| CDA [Canada's Drug Agency] and pCPA [pan-Canadian Pharmaceutical Alliance]. | 心血管
> 心血管及心臟疾病 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 10,000 | International | Sometimes | 119040619515 |
| Patient stories for CADTH [Canadian Drug and Health Technology] and INESS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | 一般健康
> 一般健康 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 10,000 | National | Sometimes | 119042243488 |
| Through the CDA-AMC [Canadian Drug Agency – Agence des médicaments du Canada]. | 癌症
> 癌症：皮膚 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 5,000 | National | Regularly | 119042855470 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA [Health Technology Assessment]) and reimbursement decision-making. | 患者倡議
> 健康活動人士 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | 患者倡議
> 健康活動人士 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Part of CDA [Canada’s Drug Agency] review process. | 呼吸系統
> 肺部疾病 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 10,000 | Regional | Rarely | 119044465336 |
| Advocating to Canadian regulatory bodies for increased scope of coverage for mTOR [mechanistic Target of Rapamycin] inhibitors. | 罕見
> 罕見疾病：其他 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 1,000 | National | Sometimes | 119045262810 |
| Sitting on advisory boards at HTAs [Health Technology Assessments] and providing patient feedback to the Federal Government. | 癌症
> 癌症：乳腺癌 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100,000 | National | Regularly | 119049015873 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services], but not for pricing, only for macro-level improvements to access. | 癌症
> 癌症：大多數類型 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 1,000 | Regional | Sometimes | 119050786265 |
| Submitted patient group input to Canadian Drug Agency regarding new medications for alopecia areata to public and private payers. | 皮膚
> 脫髮 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 5,000 | National | Sometimes | 119050829703 |
| CDA [Canadian Drug Agency] submissions, working with each provincial formulary. | 呼吸系統
> 肺纖維化 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100,000 | National | Regularly | 119050864232 |
| Meetings with INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services] and the CDA [Canadian Drug Agency – Agence des médicaments du Canada] regarding drug access issues. | 癌症
> 癌症：血液 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 5,000 | National | Regularly | 119050868250 |
| HTA [Health Technology Assessment] submissions for new treatments. | 癌症
> 癌症：膀胱 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 10,000 | National | Sometimes | 119051388329 |
| We provide patient input to Canada's Drug Agency when they are deciding whether or not to recommend public reimbursement for new drugs. | 視覺障礙
> 視覺障礙 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100,000 | National | Regularly | 119061542318 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers. We also submit on behalf of people with lived experience through the HTA [Health Technology Assessment] opportunities with CDA-AMC [Canada's Drug Agency – Agence des médicaments du Canada] and INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | 癌症
> 癌症：大多數類型 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 1,000 | National | Regularly | 119068300611 |
| Mostly drug reimbursement approval, but that touches on pricing as well. We participate in patient group submissions that are used in those reviews. We have done this for two new drugs in the past few years. | 罕見
> 龐貝氏症 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100 | National | Rarely | 119070062251 |
| We submit HTA [Health Technology Assessment] submissions to Canada Drug Agency. | 呼吸系統
> 肺纖維化 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100,000 | National | Regularly | 119070095029 |
| CDA [Canadian Drug Agency – Agence des médicaments du Canada], INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | 癌症
> 癌症：大腸直腸癌 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 10,000 | National | Regularly | 119070177334 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | 一般健康
> 肥胖症 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100,000 | International | Regularly | 119071517799 |
| CDA [Canada's Drug Agency] AMC [Agence des médicaments du Canada], INESSS [National Institute of Excellence in Health and Social Services]. | 一般健康
> 肥胖症 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | 100,000 | National | Regularly | 119072155321 |
| HTA [Health Technology Assessment] assessments and reimbursement reviews. | 病人教育
> 病人教育 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | Do not know | National | Sometimes | 119073221885 |
| We participated in a Canada Drug Agency review of COPD [Chronic Obstructive Pulmonary Disease] medication access recently. | 呼吸系統
> 肺部疾病 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | Do not know | National | Rarely | 119074014255 |
| Patient submissions to CDA [Canada's Drug Agency]. | 風濕性
> 狼瘡 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | We do not communicate with patients directly | National | Regularly | 119076616920 |
| We advocate for the approval and reimbursement of medications that improve sight or prevent sight loss. | 視覺障礙
> 視覺障礙 | 監管合作夥伴關係
> 參與健康技術評估（HTA）及報銷審查 | Do not know | National | Regularly | 119076796006 |
| We fully support new technologies and therapies to Health Canada. | 殘疾
> 殘疾：其他 | 監管合作夥伴關係
> 為市場授權申請作出貢獻 | 5,000 | National | Regularly | 119070019511 |
| Pre-budget submissions to Federal and Provincial governments and appearance before Senate and legislature committees. | 年長人士
> 年長人士 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 100,000 | National | Regularly | 119020601606 |
| Sitting on advisory boards at HTAs [Health Technology Assessments] and providing patient feedback to the Federal Government. | 癌症
> 癌症：乳腺癌 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 100,000 | National | Regularly | 119049015873 |
| Represent patient issues to regulators. | 罕見
> 罕見疾病：血液 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | We do not communicate with patients directly | National | Regularly | 119078414468 |
| Patients participate in Town Halls where some of these issues are addressed. | 血液
> 鐮狀細胞病 | 監管合作夥伴關係
> 與其他醫療倡導者 | 100 | Regional | Rarely | 119026823537 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | 視覺障礙
> 黃斑部退化 | 影響政策及立法
> 影響醫療保健政策及立法 | 100,000 | Regional | Regularly | 115043530962 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | 年長人士
> 年長人士 | 影響政策及立法
> 影響醫療保健政策及立法 | 10,000 | National | Regularly | 119044669631 |
| HTA submissions, other public consultations, awareness-building. | 皮膚
> 皮膚狀況：大多數類型 | 影響政策及立法
> 參與公眾聆訊及諮詢 | 100,000 | National | Regularly | 119022981107 |
| Provincial Legislative Advocacy days yearly. | 風濕性
> 硬皮病 | 影響政策及立法
> 參與公眾聆訊及諮詢 | 5,000 | National | Regularly | 119071951250 |
| Media representation and direct advocacy to provincial Members of Parliament. | 罕見
> 罕見疾病：遺傳性 | 影響政策及立法
> 動員議員及政治領袖 | 1,000 | Regional | Sometimes | 115035427287 |
| Pre-budget submissions to Federal and Provincial governments and appearance before Senate and legislature committees. | 年長人士
> 年長人士 | 影響政策及立法
> 動員議員及政治領袖 | 100,000 | National | Regularly | 119020601606 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | 年長人士
> 年長人士 | 影響政策及立法
> 動員議員及政治領袖 | 10,000 | National | Regularly | 119044669631 |
| Getting Besrem [immunotherapy used to treat polycythemia vera in adults] approved by Health Canada for emergency use. | 癌症
> 癌症：血液 | 影響政策及立法
> 處理醫療護理中的障礙/異常情況 | 1,000 | National | Sometimes | 119022124095 |
| We advocate for the approval and reimbursement of medications that improve sight or prevent sight loss. | 視覺障礙
> 視覺障礙 | 影響政策及立法
> 處理醫療護理中的障礙/異常情況 | Do not know | National | Regularly | 119076796006 |
| Signed letter to PCPA [Pan-Canadian Pharmaceutical Alliance] when a negotiation is taking longer than usual or when a negotiation fails. | 癌症
> 癌症：血液 | 定價及可負擔性倡議
> 倡導公平藥品定價 | 5,000 | National | Sometimes | 119020401468 |
| ... Heal Canada engages in formal submissions, consultations, advisory processes, and collaborative stakeholder dialogues to ensure patient perspectives are embedded in pricing, reimbursement, and access frameworks—particularly where traditional cost-effectiveness models fail to capture the full human, social, and system-level value of therapies. | 患者倡議
> 健康活動人士 | 定價及可負擔性倡議
> 倡導公平藥品定價 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We rally our community when there are ASM [Anti-Seizure Medication] shortages and to support price regulations for medication for patients with epilepsy. | 神經系統
> 癲癇 | 定價及可負擔性倡議
> 倡導公平藥品定價 | 5,000 | Local | Regularly | 119050807827 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers informed. | 癌症
> 癌症：大多數類型 | 定價及可負擔性倡議
> 倡導公平藥品定價 | 1,000 | National | Regularly | 119068300611 |
| I was a member of the PMRB [Patented Medicine Prices Review Board] representing the patient perspective and have written numerous submissions to the authorities about drug access and pricing. | 癌症
> 癌症：血液 | 定價及可負擔性倡議
> 倡導公平藥品定價 | 5,000 | National | Regularly | 119068939499 |
| Mostly drug reimbursement approval, but that touches on pricing as well. | 罕見
> 龐貝氏症 | 定價及可負擔性倡議
> 倡導公平藥品定價 | 100 | National | Rarely | 119070062251 |
| Signed letter to PCPA [Pan-Canadian Pharmaceutical Alliance] when a negotiation is taking longer than usual or when a negotiation fails. | 癌症
> 癌症：血液 | 定價及可負擔性倡議
> 參與價格審查委員會談判 | 5,000 | National | Sometimes | 119020401468 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance, alliance of Canada's federal, provincial, and territorial public drug plans that negotiates drug prices on behalf of public payers.]. | 免疫
> 原發性免疫缺陷病 | 定價及可負擔性倡議
> 參與價格審查委員會談判 | 5,000 | National | Sometimes | 119044550257 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | 年長人士
> 年長人士 | 定價及可負擔性倡議
> 參與價格審查委員會談判 | 10,000 | National | Regularly | 119044669631 |
| ... In the past, we have also advocated directly with the pCPA [Provincial Council for Drug Programs], which negotiates drug prices, but this is not a regular occurrence. | 視覺障礙
> 視覺障礙 | 定價及可負擔性倡議
> 參與價格審查委員會談判 | 100,000 | National | Regularly | 119061542318 |
| We write letters to pCPA [pan-Canadian Pharmaceutical Alliance] when necessary. | 癌症
> 癌症：血液 | 定價及可負擔性倡議
> 要求製造商降低銷售價格 | 10,000 | National | Regularly | 119031899906 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance]. | 免疫
> 原發性免疫缺陷病 | 定價及可負擔性倡議
> 追蹤及監測藥品定價／藥品短缺情況 | 5,000 | National | Sometimes | 119044550257 |
| We rally our community when there are ASM [Anti-Seizure Medication] shortages and to support price regulations for medication for patients with epilepsy. | 神經系統
> 癲癇 | 定價及可負擔性倡議
> 追蹤及監測藥品定價／藥品短缺情況 | 5,000 | Local | Regularly | 119050807827 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers informed. | 癌症
> 癌症：大多數類型 | 定價及可負擔性倡議
> 追蹤及監測藥品定價／藥品短缺情況 | 1,000 | National | Regularly | 119068300611 |
| Patient group submissions—not specific to pricing itself, but to approvals for coverage. | 心理健康
> 心理健康：情緒障礙 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 10,000 | National | Rarely | 119020492804 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance]. | 免疫
> 原發性免疫缺陷病 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 5,000 | National | Sometimes | 119044550257 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access through Provincial-Territorial formularies. | 神經系統
> 癲癇 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | We do not communicate with patients directly | National | Regularly | 119045277128 |
| CDA [Canadian Drug Agency] submissions, working with each provincial formulary. | 呼吸系統
> 肺纖維化 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 100,000 | National | Regularly | 119050864232 |
| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members take part in CDA [Canadian Drug Agency] surveys and sessions often. | 視覺障礙
> 視覺障礙 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | Do not know | National | Sometimes | 119063928324 |
| Mostly drug reimbursement approval, but that touches on pricing as well. | 罕見
> 龐貝氏症 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 100 | National | Rarely | 119070062251 |
| HTA submissions, other public consultations, awareness-building. | 皮膚
> 皮膚狀況：大多數類型 | 定價及可負擔性倡議
> 參與宣傳活動 | 100,000 | National | Regularly | 119022981107 |
| Getting Besrem [mmunotherapy used to treat polycythemia vera in adults] approved by Health Canada for emergency use. | 癌症
> 癌症：血液 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 1,000 | National | Sometimes | 119022124095 |
| We don't provide information for drug pricing, just advocacy for drug approvals or access. | 風濕性
> 狼瘡 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 5,000 | Regional | No | 119022371395 |
| ... Heal Canada engages in formal submissions, consultations, advisory processes, and collaborative stakeholder dialogues to ensure patient perspectives are embedded in pricing, reimbursement, and access frameworks—particularly where traditional cost-effectiveness models fail to capture the full human, social, and system-level value of therapies. | 患者倡議
> 健康活動人士 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Advocating to Canadian regulatory bodies for increased scope of coverage for mTOR [mechanistic Target of Rapamycin] inhibitors [a form of anti-cancer treatment]. | 罕見
> 罕見疾病：其他 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 1,000 | National | Sometimes | 119045262810 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access. | 神經系統
> 癲癇 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | We do not communicate with patients directly | National | Regularly | 119045277128 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services], but not for pricing, only for macro-level improvements to access. | 癌症
> 癌症：大多數類型 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 1,000 | Regional | Sometimes | 119050786265 |
| Meetings with INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services] and the CDA [Canadian Drug Agency – Agence des médicaments du Canada] regarding drug access issues. | 癌症
> 癌症：血液 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 5,000 | National | Regularly | 119050868250 |
| We frequently advocate for the approval of new drugs for market access. | 視覺障礙
> 視覺障礙 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | Do not know | National | Sometimes | 119063928324 |
| … and have written numerous submissions to the authorities about drug access and pricing. | 癌症
> 癌症：血液 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 5,000 | National | Regularly | 119068939499 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | 一般健康
> 肥胖症 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 100,000 | International | Regularly | 119071517799 |
| Patient submissions to CDA [Canada's Drug Agency]. Ongoing national advocacy for equitable access to care and treatment. | 風濕性
> 狼瘡 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | We do not communicate with patients directly | National | Regularly | 119076616920 |
| We often focus on vaccines, but not only those. We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | 年長人士
> 年長人士 | 改善存取途徑
> 倡導更廣泛的疫苗獲取途徑 | 10,000 | National | Regularly | 119044669631 |
| We provide patient input to CDA [Canada Drug Agency] when they are deciding whether or not to recommend public reimbursement for new drugs. We also provide input to provinces. | 視覺障礙
> 視覺障礙 | 改善存取途徑
> 解決在獲取和管理方面的差距 | 100,000 | National | Regularly | 119061542318 |
| There are not many new treatments for rare cancers, but when a new treatment or class is introduced, we act as Canada's advocacy group on behalf of sarcoma cancer patients. | 癌症
> 癌症：肉瘤 | 改善存取途徑
> 改善罕見/極罕見療法的獲取途徑 | 5,000 | National | Regularly | 119078449674 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA [Health Technology Assessment]) and reimbursement decision-making. | 患者倡議
> 健康活動人士 | 以實證為基礎的患者意見
> 利用患者洞察來輔助決策 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Submitted patient group input to Canadian Drug Agency regarding new medications for alopecia areata to public and private payers. | 皮膚
> 脫髮 | 以實證為基礎的患者意見
> 利用患者洞察來輔助決策 | 5,000 | National | Sometimes | 119050829703 |
| Mostly drug reimbursement approval, but that touches on pricing as well. We participate in patient group submissions that are used in those reviews. We have done this for two new drugs in the past few years. | 罕見
> 龐貝氏症 | 以實證為基礎的患者意見
> 利用患者洞察來輔助決策 | 100 | National | Rarely | 119070062251 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | 一般健康
> 肥胖症 | 以實證為基礎的患者意見
> 利用患者洞察來輔助決策 | 100,000 | International | Regularly | 119071517799 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | 患者倡議
> 健康活動人士 | 以實證為基礎的患者意見
> 向監管機構提供真實世界證據（RWE） | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| The lived experiences of patients are at the centre of Lupus Canada's work. | 風濕性
> 狼瘡 | 以實證為基礎的患者意見
> 善用患者故事及親身經歷敘述 | Do not know | National | Regularly | 119041443233 |
| Patient stories for CADTH [Canadian Drug and Health Technology] and INESS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | 一般健康
> 一般健康 | 以實證為基礎的患者意見
> 善用患者故事及親身經歷敘述 | 10,000 | National | Sometimes | 119042243488 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | 患者倡議
> 健康活動人士 | 以實證為基礎的患者意見
> 善用患者故事及親身經歷敘述 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We also submit on behalf of people with lived experience through the Health Technology Assessment opportunities with CAD-AMC [Canada's Drug Agency / l'Agence des médicaments du Canada (CDA-AMC)] and INESSS [Institut national d'excellence en santé et en services sociaux -National Institute of Excellence in Health and Social Services]. | 癌症
> 癌症：大多數類型 | 以實證為基礎的患者意見
> 善用患者故事及親身經歷敘述 | 1,000 | National | Regularly | 119068300611 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers. We also submit on behalf of people with lived experience through the HTA [Health Technology Assessment] opportunities with CDA-AMC [Canada's Drug Agency – Agence des médicaments du Canada] and INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | 癌症
> 癌症：大多數類型 | 以實證為基礎的患者意見
> 善用患者故事及親身經歷敘述 | 1,000 | National | Regularly | 119068300611 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | 患者倡議
> 健康活動人士 | 以實證為基礎的患者意見
> 進行調查/研究以產生數據 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members regularly participate in CDA [Canadian Drug Agency] surveys and sessions. | 視覺障礙
> 視覺障礙 | 以實證為基礎的患者意見
> 進行調查/研究以產生數據 | Do not know | National | Sometimes | 119063928324 |
| Representation, rights advocacy, and immigration support. | HIV
> HIV及性健康 | 機構管治
> 確保在政府諮詢機構中獲得代表席位 | 100 | National | Regularly | 115032094015 |
| We do regular submissions for HTA [Health Technology Assessment] and have active relationships with government decision-makers at many levels. | 腸胃
> 腸胃：大多數類型 | 機構管治
> 確保在政府諮詢機構中獲得代表席位 | 100,000 | National | Regularly | 119037340441 |
| ... been invited to national roundtables by governments and also by pharma, etc. | 年長人士
> 年長人士 | 機構管治
> 確保在政府諮詢機構中獲得代表席位 | 10,000 | National | Regularly | 119044669631 |
| I was a member of the PMRB [Patented Medicine Prices Review Board] representing the patient perspective. | 癌症
> 癌症：血液 | 機構管治
> 確保在政府諮詢機構中獲得代表席位 | 5,000 | National | Regularly | 119068939499 |
| There are not many new treatments for rare cancers, but when a new treatment or class is introduced, We act as Canada's advocacy group on behalf of sarcoma cancer patientsw | 癌症
> 癌症：肉瘤 | 機構管治
> 確保在政府諮詢機構中獲得代表席位 | 5,000 | National | Regularly | 119078449674 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access. | 神經系統
> 癲癇 | 機構管治
> 在多方持份者網絡中有效運作 | We do not communicate with patients directly | National | Regularly | 119045277128 |
| Representation, rights advocacy, and immigration support. | HIV
> HIV及性健康 | 維護病人權益／提升生活質素
> 保護/改善患者體驗 | 100 | National | Regularly | 115032094015 |
| We are a peer-led organization that advocates for one another on patients' rights, on care and treatment. | HIV
> HIV | 維護病人權益／提升生活質素
> 保護/改善患者體驗 | 1,000 | Local | Regularly | 119045557717 |
互動
行動與倡議
36 提及
